Hemogenyx Pharmaceuticals (LSE: HEMO) has announced the signing of a letter of intent (LOI) with closely held Cellin Technologies to explore the commercialization of its HG-CT-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) through the hospital exemption pathway under Estonia’s Medicinal Products Act.
According to Hemogenyx, the collaboration is the first potential near-term revenue opportunity for HG-CT-1. The LOI is non-binding and serves as a framework for further discussions between parties.
In a statement, Dr. Vladislav Sandler, CEO and co-founder of Hemogenyx, commented, “Our first priority is to save the lives of patients with R/R AML, for whom treatment options remain scarce. Building on this mission, the partnership with Cellin also creates a path to generate initial revenues for HG-CT-1 under Estonia’s hospital exemption pathway, while providing valuable real-world patient data to complement our Phase 1 trial and support the future development and commercialization of the therapy.”
